# Effect of a Probiotic Formula on Reducing SIBO in IBS Patients

> **NCT04316806** · NA · TERMINATED · sponsor: **AB Biotics, SA** · enrollment: 8 (actual)

## Conditions studied

- Irritable Bowel Syndrome
- Small Intestinal Bacterial Overgrowth

## Interventions

- **DIETARY_SUPPLEMENT:** Probiotic
- **DRUG:** Rifaximin

## Key facts

- **NCT ID:** NCT04316806
- **Lead sponsor:** AB Biotics, SA
- **Sponsor class:** INDUSTRY
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2020-11-20
- **Primary completion:** 2022-09-01
- **Final completion:** 2022-09-01
- **Target enrollment:** 8 (ACTUAL)
- **Why stopped:** Principal Investigator changed his job
- **Last updated:** 2022-11-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04316806

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04316806, "Effect of a Probiotic Formula on Reducing SIBO in IBS Patients". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT04316806. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*